Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical

Oncogenic fusion proteins, arising from chromosomal rearrangements, have emerged as prominent drivers of tumorigenesis and crucial therapeutic targets in cancer research. In recent years, the potential of small molecular inhibitors in selectively targeting fusion proteins has exhibited significant p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Yichao, Jiang, Caihong, Wei, Guifeng, Sun, Kai, Wang, Ruijie, Qiu, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301843/
https://www.ncbi.nlm.nih.gov/pubmed/37375228
http://dx.doi.org/10.3390/molecules28124672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301843/
https://www.ncbi.nlm.nih.gov/pubmed/37375228
http://dx.doi.org/10.3390/molecules28124672

Ejemplares similares